Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2019 08:00 ET | Quelle: Cybrexa Therapeutics

Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity

Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors Poster presentation today during AACR Annual Meeting 2019 ...
26. März 2019 09:00 ET | Quelle: Biodesix, Inc.

Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR

BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...
18. März 2019 08:00 ET | Quelle: Cybrexa Therapeutics

Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019

NEW HAVEN, Conn., March 18, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...